Pegmolesatide
ApprovedPeptide
Pegmolesatide is one of 33 small molecule programs targeting Chronic Kidney Disease. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
540 competitors in Chronic Kidney Disease
#DrugCompanyPhaseTrials
1Aranesp
AmgenPreclinical
Pegmolesatide
TThe First Affiliated Hospital of Dalian Medical University
Approved
Uloric
TakedaPreclinical
Lorelco
SanofiPreclinical
Sovaldi
GileadPreclinical
Activase
RochePreclinical
Flomax
SanofiPreclinical
Miochol
BBausch Health Americas, Inc.
Preclinical
Epoetin Beta
RochePreclinical
Genotropin
EMD SeronoPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Kidney Disease1 trial
Two Different Regiments of Pegmolesatide for Anemia in Patients With Chronic Kidney Disease Not Receiving Dialysis
Not yet recruiting·TThe First Affiliated Hospital of Dalian Medical University·Phase 4·NCT06946394·160 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pegmolesatide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details